Copenhagen 28th April 2011, 2011-04-28 14:54 CEST (GLOBE NEWSWIRE) -- Affitech A/S, (Nasdaq OMX: AFFI), the antibody medicines company, today announced that the Annual General Meeting of the Company was held on Thursday April 28th in Copenhagen at 10:00 am.
The matters decided at the Annual General Meeting were as follows:
- The Board of Directors presented the Annual Report, this was adopted and the discharge of the Board of Directors and the Management board was approved
- The Board of Directors' proposal that losses for the year be carried forward to the following year was approved
- The Board of Directors' motion to authorize the Board of Directors to acquire own shares was adopted
- The Board of Directors' motion to change the company's currently effective general guidelines for incentive payment for the Board of Directors and executive management of Affitech A/S and remuneration policy was adopted
- Aleksandr Shuster, Andrei Petrov and Keith Graham McCullagh were re-elected to the Board of Directors. Viktor Kharitonin, Pål Rødseth and Arne Handeland resigned, and Steven Morell, Igor Fisch and Yegor S. Vassetzky were elected as new members of the Board of Directors.
- Ernst & Young was elected as the Company's state authorized public accountant.
- The chairman of the meeting was authorized to file any resolutions required to be registered with the Commerce and Companies Agency
Following the General Meeting, the newly elected Board of Directors met and elected Aleksandr Shuster as Chairman and Keith Graham McCullagh as Vice Chairman.
About Affitech
Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic antibody company based in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech’s premier discovery engine for the isolation of lead antibodies to cell surface molecules. Affitech co-develops its two lead antibody drug candidates AT001/r84 and AT008/CCR4 with Russian partner NauchTekhStroy Plus. Further information is available at www.affitech.com.
Disclaimer
This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of the financial condition and operations of Affitech A/S. There are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forecasts. These factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to transact viable and profitable commercial deals, the risk of non-approval of patents not yet granted, and difficulties of obtaining relevant governmental approvals for new products.
No expressed or implied representations or warranties are given concerning Affitech A/S or the accuracy or completeness of the information provided herein, and no claims shall be made by the recipient of this news release by virtue of the information contained herein.
Contact:
Randi Krogsgaard, Director IR & Corporate Communications
Tel # +45 2320 1001, e-mail: ir@affitech.com